



Redeye will host two events with Newbury Pharmaceuticals in December

Following the recent publication of its analysis of Newbury Pharmaceuticals, Redeye will host two events where Newbury Pharmaceuticals, CEO, Lars Minor will explain more about the strategy and answer questions to the analysis

The events will be hosted by Redeye and take place online on the 14th December and in Gothenburg on the 15th December. Please visit <https://www.redeye.se/events> for more information about the two events.

Redeye published its analysis of Newbury Pharmaceuticals with the below summary.

“Redeye initiates coverage of Newbury Pharmaceuticals, a hybrid pharmaceutical company focusing on providing specialty and branded products on the Scandinavian markets. We identify rapid growth opportunities rooted in an exciting pipeline, bolstered by strong management with extensive sector expertise. We argue that the share offers de-risked exposure to an ever-growing pharmaceutical market and see several potential catalysts ahead”.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
06 December 2022 07:00:00 CET



Attachments

[Redeye will host two events with Newbury Pharmaceuticals in December](#)